Tissue penetration of meropenem in patients undergoing gynecologic surgery

Stanley Gall, David L. Hemsell, James A. McGregor, Mark G. Martens, Donald Pitkin, Sarah Allen

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The purpose of this study was to assess the tissue-penetrating ability of a new β-lactam antibiotic, meropenem, in 64 patients undergoing elective gynecologic surgery. Patients received a single 500-mg dose intravenously before surgery. Plasma and tissue concentrations of meropenem were highest at ~1 hour, and good tissue penetration was seen in the variety of specimens evaluated. The median plasma concentration at ~1 hour was 13.3 μg/mL. The median fluid and tissue concentrations at ~1 hour were as follows: cervix, 8.5 μg/g; endometrium, 2.3 μg/g; fallopian tube, 1.9 μg/g; myometrium, 3.6 μg/g; ovary, 2.3 μg/g; and uterus, 2.3 μg/g. These tissue concentrations exceed the MICs of meropenem for 90% of typical pathogens associated with gynecologic infections. Meropenem readily penetrates gynecologic tissue. A single 500-mg dose provides adequate tissue concentrations for treatment of gynecologic infections caused by susceptible pathogens.

Original languageEnglish (US)
JournalClinical Infectious Diseases
Volume24
Issue numberSUPPL. 2
StatePublished - 1997

Fingerprint

meropenem
Gynecologic Surgical Procedures
Lactams
Fallopian Tubes
Myometrium
Endometrium
Infection
Cervix Uteri
Uterus
Ovary

ASJC Scopus subject areas

  • Immunology

Cite this

Gall, S., Hemsell, D. L., McGregor, J. A., Martens, M. G., Pitkin, D., & Allen, S. (1997). Tissue penetration of meropenem in patients undergoing gynecologic surgery. Clinical Infectious Diseases, 24(SUPPL. 2).

Tissue penetration of meropenem in patients undergoing gynecologic surgery. / Gall, Stanley; Hemsell, David L.; McGregor, James A.; Martens, Mark G.; Pitkin, Donald; Allen, Sarah.

In: Clinical Infectious Diseases, Vol. 24, No. SUPPL. 2, 1997.

Research output: Contribution to journalArticle

Gall, S, Hemsell, DL, McGregor, JA, Martens, MG, Pitkin, D & Allen, S 1997, 'Tissue penetration of meropenem in patients undergoing gynecologic surgery', Clinical Infectious Diseases, vol. 24, no. SUPPL. 2.
Gall, Stanley ; Hemsell, David L. ; McGregor, James A. ; Martens, Mark G. ; Pitkin, Donald ; Allen, Sarah. / Tissue penetration of meropenem in patients undergoing gynecologic surgery. In: Clinical Infectious Diseases. 1997 ; Vol. 24, No. SUPPL. 2.
@article{97db56447b23487fa97096d43ba005e3,
title = "Tissue penetration of meropenem in patients undergoing gynecologic surgery",
abstract = "The purpose of this study was to assess the tissue-penetrating ability of a new β-lactam antibiotic, meropenem, in 64 patients undergoing elective gynecologic surgery. Patients received a single 500-mg dose intravenously before surgery. Plasma and tissue concentrations of meropenem were highest at ~1 hour, and good tissue penetration was seen in the variety of specimens evaluated. The median plasma concentration at ~1 hour was 13.3 μg/mL. The median fluid and tissue concentrations at ~1 hour were as follows: cervix, 8.5 μg/g; endometrium, 2.3 μg/g; fallopian tube, 1.9 μg/g; myometrium, 3.6 μg/g; ovary, 2.3 μg/g; and uterus, 2.3 μg/g. These tissue concentrations exceed the MICs of meropenem for 90{\%} of typical pathogens associated with gynecologic infections. Meropenem readily penetrates gynecologic tissue. A single 500-mg dose provides adequate tissue concentrations for treatment of gynecologic infections caused by susceptible pathogens.",
author = "Stanley Gall and Hemsell, {David L.} and McGregor, {James A.} and Martens, {Mark G.} and Donald Pitkin and Sarah Allen",
year = "1997",
language = "English (US)",
volume = "24",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Tissue penetration of meropenem in patients undergoing gynecologic surgery

AU - Gall, Stanley

AU - Hemsell, David L.

AU - McGregor, James A.

AU - Martens, Mark G.

AU - Pitkin, Donald

AU - Allen, Sarah

PY - 1997

Y1 - 1997

N2 - The purpose of this study was to assess the tissue-penetrating ability of a new β-lactam antibiotic, meropenem, in 64 patients undergoing elective gynecologic surgery. Patients received a single 500-mg dose intravenously before surgery. Plasma and tissue concentrations of meropenem were highest at ~1 hour, and good tissue penetration was seen in the variety of specimens evaluated. The median plasma concentration at ~1 hour was 13.3 μg/mL. The median fluid and tissue concentrations at ~1 hour were as follows: cervix, 8.5 μg/g; endometrium, 2.3 μg/g; fallopian tube, 1.9 μg/g; myometrium, 3.6 μg/g; ovary, 2.3 μg/g; and uterus, 2.3 μg/g. These tissue concentrations exceed the MICs of meropenem for 90% of typical pathogens associated with gynecologic infections. Meropenem readily penetrates gynecologic tissue. A single 500-mg dose provides adequate tissue concentrations for treatment of gynecologic infections caused by susceptible pathogens.

AB - The purpose of this study was to assess the tissue-penetrating ability of a new β-lactam antibiotic, meropenem, in 64 patients undergoing elective gynecologic surgery. Patients received a single 500-mg dose intravenously before surgery. Plasma and tissue concentrations of meropenem were highest at ~1 hour, and good tissue penetration was seen in the variety of specimens evaluated. The median plasma concentration at ~1 hour was 13.3 μg/mL. The median fluid and tissue concentrations at ~1 hour were as follows: cervix, 8.5 μg/g; endometrium, 2.3 μg/g; fallopian tube, 1.9 μg/g; myometrium, 3.6 μg/g; ovary, 2.3 μg/g; and uterus, 2.3 μg/g. These tissue concentrations exceed the MICs of meropenem for 90% of typical pathogens associated with gynecologic infections. Meropenem readily penetrates gynecologic tissue. A single 500-mg dose provides adequate tissue concentrations for treatment of gynecologic infections caused by susceptible pathogens.

UR - http://www.scopus.com/inward/record.url?scp=0030891496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030891496&partnerID=8YFLogxK

M3 - Article

VL - 24

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - SUPPL. 2

ER -